| |
EQ-5D Utility score (mean ± SD, n)
|
EQ-VAS score (mean ± SD, n)
|
Change in EQ-5D Dimension level with limitation from baseline to 3-month (%)
|
|---|
|
Baseline
|
3-month
|
Difference
|
p value*
|
Baseline
|
3-month
|
Difference
|
p value*
|
Mobility
|
Self-care
|
Usual Activities
|
Pain/Discomfort
|
Depression/Anxiety
|
|---|
|
GRS Group
| | | | | | | | | | | | | |
|
GRS Better
|
0.58 ± 0.28 (20)
|
0.76 ± 0.26 (20)
|
0.18 ± 0.18 (20)
|
< 0.001
|
65.90 ± 18.13 (20)
|
76.65 ± 14.00 (20)
|
10.75 ± 15.33 (20)
|
0.005
|
− 15.0% (20)
|
− 15.0% (20)
|
− 15.0% (20)
|
− 40% (20)
|
− 20% (20)
|
|
Effect size
| | |
0.666
| | | |
0.664
| | | | | | |
|
GRS Same
|
0.71 ± 0.23 (44)
|
0.79 ± 0.17 (44)
|
0.08 ± 0.17 (44)
|
0.002
|
74.59 ± 15.22 (44)
|
76.32 ± 11.54 (44)
|
1.73 ± 12.60 (44)
|
0.368
|
− 9.1% (44)
|
− 2.3% (44)
|
− 2.3% (44)
|
− 13.6% (44)
|
0% (44)
|
|
Effect size
| | |
0.396
| | | |
0.128
| | | | | | |
|
GRS Worse
|
0.61 ± 0.27 (35)
|
0.53 ± 0.30 (35)
|
− 0.08 ± 0.28 (35)
|
0.092
|
67.37 ± 15.22 (35)
|
62.43 ± 18.08 (35)
|
− 4.94 ± 18.31 (35)
|
0.120
|
14.3% (35)
|
2.9% (35)
|
8.6% (35)
|
22.9% (35)
|
2.9% (35)
|
|
Effect size
| | |
0.280
| | | |
0.296
| |
p value#
|
| | | | | | | | | |
< 0.001
|
< 0.001
|
< 0.001
|
0.021
|
< 0.001
|
|
Overall
|
0.65 ± 0.26 (99)
|
0.69 ± 0.27 (99)
|
0.04 ± 0.24 (99)
|
0.074
|
70.28 ± 16.33 (99)
|
71.47 ± 15.97 (99)
|
1.19 ± 16.24 (99)
|
0.467
|
− 2.2% (99)
|
− 2.0% (99)
|
− 1.0% (99)
|
− 6.1% (99)
|
− 3.0% (99)
|
|
Effect size
| | |
0.151
| | | |
0.074
| | | | | | |
|
Mean GRS†
| | |
0.589**
| | | |
0.495**
| | | | | | |
- GRS, global rating scale
- *Difference between baseline and 3-month EQ-5D Utility and EQ-5D VAS scores tested by paired t-tests
- #EQ-5D-5L dimension responses of moderate, severe and very severe were grouped into the ‘with limitation’ category; difference in proportions among GRS groups tested by Chi-square tests
- †Correlation between mean GRS score and EQ-5D-5L utility or VAS score, tested by Spearman correlation; **p < 0.001
